190 related articles for article (PubMed ID: 19661311)
1. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
Kim JC; Shin ES; Kim CW; Roh SA; Cho DH; Na YS; Kim TW; Kim MB; Hyun YL; Ro S; Kim SY; Kim YS
Anticancer Res; 2009 Aug; 29(8):3027-34. PubMed ID: 19661311
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.
Kim JC; Kim DD; Lee YM; Kim TW; Cho DH; Kim MB; Ro SG; Kim SY; Kim YS; Lee JS
Int J Colorectal Dis; 2009 Feb; 24(2):209-18. PubMed ID: 18830613
[TBL] [Abstract][Full Text] [Related]
3. In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs.
Yoon SN; Roh SA; Cho DH; Kim MB; Hyun YL; Ro S; Kim BS; Kim SY; Kim YS; Kim JC
Hepatogastroenterology; 2010; 57(99-100):657-62. PubMed ID: 20698245
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
5. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas.
Kim JC; Roh SA; Cho DH; Kim TW; Yoon SN; Kim CW; Yu CS; Kim SY; Kim YS
Anticancer Res; 2009 Aug; 29(8):3115-23. PubMed ID: 19661324
[TBL] [Abstract][Full Text] [Related]
6. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
7. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
10. Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2007; 12(1):71-6. PubMed ID: 17436405
[TBL] [Abstract][Full Text] [Related]
11. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer.
Sung MW; Waxman S
Anticancer Res; 2007; 27(2):995-1001. PubMed ID: 17465233
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
Mutze K; Langer R; Becker K; Ott K; Novotny A; Luber B; Hapfelmeier A; Göttlicher M; Höfler H; Keller G
Ann Surg Oncol; 2010 Dec; 17(12):3336-43. PubMed ID: 20585871
[TBL] [Abstract][Full Text] [Related]
13. Variation in the cost of medications for the treatment of colorectal cancer.
Ferro SA; Myer BS; Wolff DA; Poniewierski MS; Culakova E; Cosler LE; Scarpace SL; Khorana AA; Lyman GH
Am J Manag Care; 2008 Nov; 14(11):717-25. PubMed ID: 18999906
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Flis S; Gnyszka A; Spławiński J
Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors as anti-neoplastic agents.
Batty N; Malouf GG; Issa JP
Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
[TBL] [Abstract][Full Text] [Related]
16. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
Benoist S; Nordlinger B
Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
[TBL] [Abstract][Full Text] [Related]
17. L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma.
Ma Q; Wang Y; Gao X; Ma Z; Song Z
Clin Cancer Res; 2007 Dec; 13(24):7407-12. PubMed ID: 18094424
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Shiozawa K; Nakanishi T; Tan M; Fang HB; Wang WC; Edelman MJ; Carlton D; Gojo I; Sausville EA; Ross DD
Clin Cancer Res; 2009 Mar; 15(5):1698-707. PubMed ID: 19223502
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China.
Song W; Wu SJ; He YL; Cai SR; Zhang CH; Zhang XH; Zhan WH
Chin Med J (Engl); 2009 Jul; 122(13):1486-91. PubMed ID: 19719934
[TBL] [Abstract][Full Text] [Related]
20. Anticancer chemosensitivity and growth rate of freshly separated human colorectal cancer cells assessed by in vitro DNA synthesis inhibition assay.
Kawabata K; Nio Y; Imamura M; Fukumoto M
Anticancer Res; 1998; 18(3A):1633-40. PubMed ID: 9673382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
